0
0
The European Commission has granted approval to Vertex Pharmaceuticals’ new cystic fibrosis (CF) treatment, Alyftrek, marking a significant milestone for patients and the company. Alyftrek is a once-daily, next-generation triple combination therapy consisting of vanzacaftor, tezacaftor, and deutivacaftor. The approval covers individuals aged 6 years and older with at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Cystic fibrosis is a rare, life-shortening genetic disorder affecting more than 109,000 people worldwide, including 94,000 in North America, Europe, and Australia. The disease is caused by mutations in the CFTR gene, leading to impaired salt and water flow in various organs and resulting in thick, sticky mucus, chronic lung infections, and progressive organ damage.
Alyftrek demonstrated superior efficacy compared to Vertex’s previous leading therapy, Kaftrio (known as Trikafta in the U.S.), in head-to-head clinical trials. The new therapy showed greater improvements in CFTR function and a more substantial reduction in sweat chloride levels, a key marker for CF disease activity.
Following the European approval, eligible patients in Ireland, Denmark, and Germany are expected to gain access to Alyftrek soon. The drug is already approved in the United States and the United Kingdom, and generated $53.9 million in revenue for Vertex in the first quarter of 2025.
Vertex’s stock responded positively to the news, trading about 1% higher at the time of the announcement. The company’s shares are up approximately 12% year-to-date, despite being down 4% over the past 12 months.
“This approval represents another important step forward for the cystic fibrosis community and reinforces Vertex’s commitment to developing transformative therapies for people living with this challenging disease,” said a company spokesperson.
Disclaimer:
This article is based on publicly available information as of July 2, 2025. The clinical benefits and long-term safety of Alyftrek will continue to be monitored as it becomes more widely used. Patients should consult healthcare professionals for advice on treatment options. The information provided is not intended as medical advice or as a substitute for professional care.
